Dyne Therapeutics (DYN) last night announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen ...
Robust improvement demonstrated across diverse set of clinical measures -- Patient-reported outcomes support clinical meaningfulness of ...